利奥西呱治疗结节病相关肺动脉高压:为期1年双盲安慰剂对照试验结果
这项双盲安慰剂对照试验将16例经右心导管确诊的结节病相关肺动脉高压患者按1:1随机分配至利奥西呱组或安慰剂组,主要终点为临床恶化时间。结果显示安慰剂组8例中5例达到临床恶化标准,而利奥西呱组无 qualifying 事件,且利奥西呱组6分钟步行距离中位数增加42.7米,安慰剂组下降55.9米。
要点
- 利奥西呱可延长结节病相关肺动脉高压患者的临床恶化时间。
- 利奥西呱组6分钟步行距离中位数增加42.7米,安慰剂组下降55.9米。
- 利奥西呱组未发生与药物相关的显著不良事件。
核心结论
- 在为期1年的研究中,利奥西呱能有效预防结节病相关肺动脉高压患者的临床恶化并改善运动能力。
研究设计与样本
- 双盲安慰剂对照试验,16例经右心导管确诊的结节病相关肺动脉高压患者按1:1随机分配至利奥西呱组(n=8)或安慰剂组(n=8)。
主要发现
- 安慰剂组8例中5例达到临床恶化标准,利奥西呱组无患者发生符合标准的事件。
- 未发生与利奥西呱相关的显著不良事件。
临床怎么用
- 对于结节病相关肺动脉高压患者,利奥西呱可考虑用于预防临床恶化并改善运动能力。
局限性
- 样本量小(共16例),可能限制结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Riociguat is effective in delaying the time to clinical worsening (TCW) in patients with groups 1 and 4 pulmonary hypertension. RESEARCH QUESTION: Is riociguat more effective than placebo in prolonging TCW in sarcoidosis-associated pulmonary hypertension (SAPH)? STUDY DESIGN AND METHODS: This was a double-blind placebo-controlled trial. Patients with SAPH confirmed by right heart catheterization were randomized 1:1 to riociguat or placebo. Patients underwent 6-min walk distance (6MWD) and spirometry testing every 8 weeks. The primary end point was TCW, which was defined by the time to the first of the following: (1) all-cause mortality, (2) need for hospitalization because of worsening cardiopulmonary status attributable to progression of disease, (3) > 50 m decrease in the 6MWD test, or (4) worsening of World Health Organization functional class. RESULTS: A total of 16 patients were randomized to riociguat (n = 8) or placebo (n = 8). No difference was found in pulmonary artery mean, pulmonary vascular resistance, initial 6MWD, or FVC between the two groups. Five of eight patients who received placebo met TCW criteria, whereas none of the patients who received riociguat experienced a qualifying event. By log-rank analysis, patients who received riociguat were in the study for a significantly longer period (χ 2 = 6.259; P = .0124). The 6MWD decreased in the placebo group (median, -55.9 m; range, -176.8 to 60 m), but rose in the riociguat group (median, +42.7 m; range, -7.5 to +91.4 m; P = .0149), with a placebo-corrected difference of 94 m (P < .01). Four of eight patients who received riociguat, but only 1 of 8 patients who received placebo, showed a > 30-m improvement in 6MWD (P > .05). No significant adverse events associated with riociguat occurred. INTERPRETATION: Over the 1 year of the study, riociguat was effective in preventing clinical worsening and improving exercise capacity in patients with SAPH. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02625558; URL: www.clinicaltrials.gov.
引用
- Baughman RP, Shlobin OA, Gupta R, et al. Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial. Chest. 2021. PMID: 34363816. doi:10.1016/j.chest.2021.07.2162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。